PT Naleya Genomik Indonesia · Established 2022
Omics
for
Indonesia.
High-quality, affordable and accessible genomic testing, for the hospitals, clinics and families who need it.
- 10,000+ Genetic tests conducted
- 150+ Hospitals and clinics in our network
- 1,000+ Doctors who have prescribed our tests
- 30+ Cities and regions across Indonesia
Who we are
A BGI joint venture, built for Indonesia.
PT Naleya Genomik Indonesia was established in 2022 as a joint venture with BGI Genomics, part of BGI Group. Our laboratory was inaugurated in February 2023, witnessed by Indonesia's Ministry of Health and Dr. Yin Ye.
Our purpose is to make high-quality, affordable and accessible genomic testing available to everyone who needs it.
- 2022 Company established as a joint venture with BGI Genomics.
- Feb 2023 Laboratory inaugurated, witnessed by Indonesia's Ministry of Health.
- #1 Commercial genomic laboratory in Indonesia.
Solutions
Six solutions, one laboratory.
Start with the pillar that matches your clinic or your question.
-
01
Reproductive Health
NIPT, carrier screening, PGT-A and newborn screening, from pre-pregnancy through childhood.
View tests -
02
Oncology
Hereditary cancer risk, HPV genotyping, tumour profiling and minimal residual disease.
View tests -
03
Infectious Disease
Targeted and metagenomic sequencing to name the pathogen behind a difficult infection.
View tests -
04
Chronic Disease
APOE for Alzheimer's risk, biological age and whole-panel wellness screening.
View tests -
05
Precision Medicine Lab Service
Sequencing capacity, clinical panels and reporting for partner laboratories.
Talk to our team -
06
Multi-Omics Service and Gene Synthesis
Multi-omics support and gene synthesis for research programmes and clinical development.
Talk to our team
Available tests NALEYA® NIPT · NALEYA® PGT-A · NALEYA® THALASEQ · NALEYA® CNV-SEQ · NALEYA® HPV · COLOTECT
From sample to report
One laboratory, sample to report.
Samples are logged, analysed and reported under one quality system.
-
01
Sample collected
Blood, saliva or a swab is taken at your clinic or hospital.
-
02
Logged and checked
The sample is registered and checked against the requisition before it enters the pipeline.
-
03
Analysed
Runs are processed on DNBSEQ and CycloneSEQ platforms, under one quality system.
-
04
Report issued
The result is prepared and returned to the clinician who ordered it.
Sequencing platforms
DNBSEQ-G400 · DNBSEQ-G99 · DNBSEQ-E25 · CYCLONESEQ-WT02 · BGI LMSQ-1000
First and only sequencer with a CE-IVD certificate in Indonesia.
Who we work with
Hospitals, laboratories, universities, and the people they serve.
One laboratory behind six kinds of partner.
Government-backed partnership
NGI works with BRIN, Kemenkes and BGS on national strategic programmes, and with BGI on national-level research and talent incubation.
About the company-
Hospital
Referral testing, clinical panels and reporting for your department or clinic.
-
Consumer
Screening you can order yourself, with a report written to be understood.
-
Laboratory
Sequencing capacity and clinical panels beyond what your own bench can run.
-
Universities and colleges
Teaching, curriculum and joint research with our laboratory.
-
Research institute
Multi-omics support, gene synthesis and sequencing for your studies.
-
Pharmaceuticals company
Trial testing and therapy guidance panels for your programmes.
Talk to the laboratory.
Bring a referral, a research question or a screening programme. We will tell you which test fits, and what it needs.
Omics untuk Indonesia